published on 01/12/2026 at 19:27 from Symrise AG (ETR:SY1)

EQS-Adhoc: Symrise AG decides to divest its terpenes business and makes non-cash impairment. Symrise AG's investment in Swedencare AB is subject to a non-cash impairment.

EQS-Ad-hoc: Symrise AG / Key word(s): Miscellaneous
Symrise AG decides to divest its terpenes business and makes non-cash impairment. Symrise AG's investment in Swedencare AB is subject to a non-cash impairment.

12-Jan-2026 / 19:27 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014

Symrise AG decides to divest its terpenes business and makes non-cash impairment

Symrise AG's investment in Swedencare AB is subject to a non-cash impairment

This publication contains two separate independent inside information.

Symrise AG is in advanced talks with potential interested parties about the sale of its terpenes business. This is a structured bidding process. Based on the offers received so far, the international accounting standard IFRS 5 will be applied. In this context, a non-cash impairment charge of approximately EUR 145 million is recorded in the fourth quarter of 2025. This has a negative impact on Symrise AG's EBIT.
According to preliminary calculations, a non-cash impairment in the value of the investment in Sweden-listed Swedencare AB will lead to a material deviation from the expected result for the 2025 financial year compared to current capital market expectations and the published forecast. Symrise AG will record a non-cash impairment charge of the investment in Swedencare AB in the amount of EUR 150 million in the fourth quarter of 2025. This has a negative impact on EBITDA.

Neither measure has any impact on the liquidity and/or operating business of Symrise AG. They will be adjusted as part of the earnings reporting.

Media contact: Investor Relations Contact
Bernhard Kott René Weinberg
Phone: +49 (0)5531 90-1721 Phone: +49 (0)5531 90-1879
E-mail: bernhard.kott@symrise.com E-mail: rene.weinberg@symrise.com

End of Inside Information

12-Jan-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News

Language:	English
Company:	Symrise AG
	Mühlenfeldstraße 1
	37603 Holzminden
	Germany
Phone:	+49 (0)5531 90 0
E-mail:	ir@symrise.com
Internet:	www.symrise.com
ISIN:	DE000SYM9999, DE000SYM7787, DE000SYM7704
WKN:	SYM999
Indices:	DAX
Listed:	Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID:	2258790


End of Announcement	EQS News Service

2258790 12-Jan-2026 CET/CEST

Symrise AG Non-cash Impairment Divest Swedencare AB Terpenes Business

See all Symrise AG news